Beijing, China

Lieming Ding

This inventor holds 14 USPTO granted patents and 35 published patent applications, plus 9 CIPO patents and 8 EPO patents. Top assignees: Betta Pharmaceuticals Co., Ltd., Beta Pharma, Inc.. Active years: 2014-2025.

USPTO Granted Patents = 14 

% Patents Active = 71.4

 

 

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 10(Granted Patents)


Location History:

  • Beijing, CN (2015 - 2017)
  • Hangzhou, CN (2014 - 2022)
  • Zhejiang, CN (2017 - 2024)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Lieming Ding

Introduction: Lieming Ding is a pioneering inventor based in Beijing, China, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Lieming Ding holds several patents in the areas of artificial intelligence, robotics, and renewable energy technologies, showcasing his continuous dedication to pushing the boundaries of technological advancement.

Career Highlights: With a career spanning over two decades, Lieming Ding has worked with prestigious research institutions and leading tech companies, where he has spearheaded projects that have revolutionized industries and improved the quality of life for many.

Collaborations: Throughout his career, Lieming Ding has collaborated with top engineers, scientists, and researchers from around the world, fostering a culture of innovation and knowledge exchange that has led to the development of cutting-edge technologies.

Conclusion: Lieming Ding's relentless pursuit of innovation and his passion for creating solutions to complex challenges have solidified his reputation as a visionary inventor in the global tech community. His work continues to inspire future generations of inventors and shape the technological landscape for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…